Anemia and radiotherapy;Anémie et radiothérapie

Bulletin du Cancer

Volumn 90, Issue 4 SPEC. ISS., 2003, Pages

  Pasquier, David ^a   Lartigau, Eric ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Anaemia; Radiotherapy; Tumour hypoxia

Indexed keywords

RADIOSENSITIZING AGENT;

ANEMIA; ANGIOGENESIS; CANCER RADIOTHERAPY; HYPOXIA; IONIZING RADIATION; OXYGEN CONSUMPTION; REVIEW;

ANEMIA; BLOOD TRANSFUSION; CELL HYPOXIA; ERYTHROPOIETIN; HEMOGLOBIN A; HUMANS; NEOPLASMS; OXYGEN; OXYGEN CONSUMPTION; PARTIAL PRESSURE; RADIATION-SENSITIZING AGENTS;

EID: 0037833474     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Molls M, Stadler P, Becker A, Feldmann H, Dunst J. Relevance of oxygen in radiation oncology: mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998 ; 174 (suppl. IV): 13-6.
2. Olive PL, Vikse CM, Vandetbyl S. Increase in the fraction of necrotic, not apoptotic, cells in SiHa xenograft tumours shortly after irradiation. Radiother Oncol 1999 ; 50 : 113-9.
3. Raleigh J, Dewhitst M, Thrall D. Measuring tumor hypoxia. Semin Radiat Oncol 1996 ; 46 : 229-37.
4. Vaupel P, Thews O, Kelleher D, Hoeckel M. Oxygenation of human tumors : the Mainz experience. Strahlenther Onkol 1998 ; 174 (suppl. IV): 6-12.
5. Reynolds T, Rockwell S, Glazer P. Generic instability induced by the tumor microenvironment. Cancer Res 1996 ; 56 : 5754-7.
6. Sutherland R, Ausserer W, Murphy B, Laderoute K. Tumor hypoxia and heterogeneity: challenges and opportunities for the future. Semin Radiat Oncol 1996 ; 6 : 59-70.
7. Tufto I, Lyng H, Rofstad E. Interstitial fluid pressure, perfusion rate and oxygen tension in human melanoma xenografts. Br J Cancer 1996 ; 27 : S252-5.
8. Young SD, Marshall RS, Hill RP. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci 1988 ; 85 : 9533-7.
9. Gray LH, Conger AS, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen in dissolved tissues at the time of irradiation as a factor of radiotherapy. Br J Radiol 1953 ; 26 : 638-48.
10. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and possible implications for radiotherapy. Br J Cancer 1955 ; 9 : 539.
11. Brizel D, Sibley G, Prosnitz L, Sher R, Dewhirst M. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997 ; 38 : 285-9.
12. Brizel DM, Scully SP, Harrelson JM. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996 ; 56 : 941-3.
13. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998 ; 48 : 149-56.
14. Höckel M, Schlenger K, Mitze M, Schaeffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol 1996 ; 6 : 3-9.
15. Höckel M, Vorndran B, Schlenger K, Baussmann E, Knapstein P. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993 ; 51 : 141-9.
16. Horsman M. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998 ; 42 : 701-4.
17. Lartigau E, Le Ridant AM, Lambin P, Weeger P, Martin L, Sigal R, et al. Oxygenation of head and neck tumors. Cancer 1993 ; 71 : 2319-25.
18. 2) in metastatic melanoma. Melanoma Res 1997 ; 7 : 400-6.
19. Lartigau E, Lusinchi A, Weeger P, Wibault P, Luboinski B, Eschwege F, et al. Increased tumour oxygenation during accelerated radiotherapy of head and neck carcinoma. Europ J Cancer 1998 ; 34 : 856-61.
20. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996 ; 41 : 31-9.
21. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996 ; 16 : 4604-13.
22. 2 - dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci 1998 ; 95 : 7987-92.
23. Maxwell P, Dachs GU, Gleadle J, Gleadle J. Hypoxia inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc Natl Acad Sci 1997 ; 94 : 8104-9.
24. Graeber T, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996 ; 379 : 88-91.
25. Russo CA, Weber TK, Volpe CM, Stoler DL, Petrelli NJ, Rodriguez-Bigas M, et al. An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Res 1995 ; 55 : 1122-8.
26. Miller C, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990 ; 322 : 1689-92.
27. Schapira L, Antin JH, Ransil BJ, Antman KH, Eder JP, McGarigle CJ, et al. Serum etythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990 ; 76 : 2354-9.
28. Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschläger C, et al. Severe anaemia is associated with poor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000 ; 46 : 459-66.
29. Bush RS. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986 ; 12 : 2047-50.
30. Evans JC, Bergsjø P. The Influence of anemia on the results of radiotherapy in carcinoma of the cervix. Radiology 1965 ; 84 : 709-17.
31. Dische S. Radiotherapy and anaemia: the clinical experience. Radiother Oncol 1991 ; 20 : 35-40.
32. Girinski T, Pejovic-Lenfant MH, Bourhis J, Campana F, Cosset JM, Petit C, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989 ; 16 : 37-42.
33. Grant DG, Hussain A, Hurman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol 1999 ; 113 : 829-33.
34. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P, eds. Medical radiology-diagnostic imaging and radiation oncology. Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology. Berlin: Springer, 1998 ; 101-12.
35. Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998 ; 42 : 1069-75.
36. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998 ; 41 : 347-53.
37. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995 ; 13 : 2077-83.
38. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiation Oncol Biol Phys 1997 ; 38 : 1007-11.
39. Lartigau E, Guichard M. L'effet oxygène: bilan des connaissances et applications pratiques. Bull Cancer 1991 ; 78 : 441-53.
40. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxla in solid tumors. Oncol Res 1994 ; 6 : 509-18.
41. Overgaard J, Hansen HS, Ovetgaard M, Basrholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish Head and Neck Cancer Study (Dahanca) Protocol 5-85. Radiother Oncol 1998 ; 46 : 135-46.
42. Haffry BG, Son YH, Sasaki CT, Papac R, Fischer D, Rockwell S, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993 ; 27 : 241-50.
43. Larrigau E, Guichard M. Does rirapazamine (SR-4233) have any cytotoxic or sensitizing effect on 3 human cell lines at clinically relevant partial oxygen pressure ? Int J Radiat Biol 1995 ; 2 : 211-6.
44. Henk JM, Kunkler PB, Smith CW. Radiotherapy and hyperbaric oxygen in head and neck cancer: final report of first controlled clinical trial. Lancet 1977 ; 2 : 101-3.
45. Watson ER, Halnan KE, Dische S, Saunders MI, Cade IS, McEwen JB, et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978 ; 51 : 879-87.
46. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993 ; 27 : 1147-51.
47. Lavey RS. Clinical experience using erythropoietin during radiation therapy. In: Tumor hypoxia. Vaupel P & Kelleher DK eds., Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 1999 : 99-105.
48. Spivak JL. Application of recombinant human erythropoietin in oncology. Cancer Invest 1990 ; 8 : 301-2.
49. Kelleher D, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? Srrahlenther Onkol 1998 ; 174 (suppl. IV): 20-3.
50. Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994 ; 29 : 1079-84.
51. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M 3rd, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998 ; 77 : 1996-2002.
52. Glaser C, Millesi W, Wanschirz F, Schüll B, Lang S, Leitha T, et al. R-Hu erythropoietin treatement increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patient with oral squamous cell carcinoma: a 17 month follow up. J Clin Oncol 1999 ; S18 : 399a.
53. Antonadou D, Cardamakis E, Sarris G, Tzigounis V, Throuvalas V Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998 ; S48 : 483.
54. Groupe de travail SOR. Standards, options et recommandations pour l'urilisation de l'érythropoïétine en cancérologie. Bull Cancer 1998 ; 85 : 337-46.